Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496417 · ClinicalTrials.gov registry record · NA
Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores
A NA study, sponsored by University of Maryland.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01496417 is a NA study that has completed, run by University of Maryland. The registered enrollment target is 20 participants.
The verdict
NCT01496417, a NA study, has completed, sponsored by University of Maryland.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This will be a pilot study to investigate the use of belatacept (BMS) therapy in kidney transplant patients who have a MAPI score of greater than or equal to 8. The MAPI (Maryland Aggregate Pathology Index) score is a preimplantation donor scoring system which has five histopathological parameters that impact long-term kidney outcomes. Many kidney transplant recipients use calcineurin inhibitors (CNIs) as one of their anti-rejection medi cations. Kidney function may be affected by anti-rejection medications known as calcineurin inhibitors (CNIs). Sometimes CNIs can lead to toxicities and eventually loss of the kidney or episodes of chronic allograft nephropathy (CAN). Avoiding CNI immunosuppression and using belatacept therapy (BMS) instead, may be associated with improved kidney transplant outcomes.
Interventions
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-03 |
| Est. Completion | 2018-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01496417
The ClinicalTrials.gov registry entry for NCT01496417 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belatacept is the first listed.
NCT01496417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01496417 about?
NCT01496417 is a clinical study titled "Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores". This will be a pilot study to investigate the use of belatacept (BMS) therapy in kidney transplant patients who have a MAPI score of greater than or equal to 8. The MAPI (Maryland Aggregate Pathology Index) score is a preimplantation donor scoring system which has five histopathological parameters t...
What is the current status of trial NCT01496417?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2012-03. Estimated completion is 2018-03-01.
What interventions are being tested in trial NCT01496417?
The interventions under investigation include: Belatacept (DRUG).
Who is sponsoring clinical trial NCT01496417?
This trial is sponsored by University of Maryland, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.